Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Germline pathogenic or likely pathogenic variants in the CTNNA1 gene predispose to hereditary diffuse gastric cancer and lobular breast cancer, a cancer susceptibility syndrome inherited in an autosomal dominant pattern.
No clinical trials have been registered for CTNNA1-related diffuse gastric and lobular breast cancer syndrome.
4 publications have been identified in PubMed for CTNNA1-related diffuse gastric and lobular breast cancer syndrome. Kisho has analyzed 3 by research type. Research spans Review / Meta-Analysis (67%) and Case Report / Case Series (33%).
Vaessen C (2026). [PMID: 41517846](https://pubmed.ncbi.nlm.nih.gov/41517846/). *J Gastric Cancer*. [Review / Meta-Analysis]
Wiese J (2025). [PMID: 40974220](https://pubmed.ncbi.nlm.nih.gov/40974220/). *J Investig Med High Impact Case Rep*. [Case Report / Case Series]
Fernández Aceñero MJ (2024). [PMID: 39057027](https://pubmed.ncbi.nlm.nih.gov/39057027/). *Curr Issues Mol Biol*. [Review / Meta-Analysis]
Data assembled from 2 of 12 sources · Last updated Sep 20, 2026, 4:39 PM UTC
Common questions about CTNNA1-related diffuse gastric and lobular breast cancer syndrome